Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 8/20 | 0.40 |
| ▸ | JAK3 | P52333 | 7/20 | 0.36 |
| ▸ | BTK | Q06187 | 5/20 | 0.35 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1629421 | 1.00 | TEAD1 (0.40) | TEAD1JAK3BTKTEAD3 | |
| SCHEMBL1630022 | 1.00 | TEAD1 (0.40) | TEAD1JAK3BTKTEAD3 | |
| SCHEMBL410336 | 0.90 | JAK3 (0.41) | TEAD1JAK3BTK | |
| SCHEMBL1628865 | 0.90 | JAK3 (0.41) | TEAD1JAK3BTK | |
| SCHEMBL1628867 | 0.90 | JAK3 (0.41) | TEAD1JAK3BTK | |
| SCHEMBL409261 | 0.89 | TEAD1 (0.45) | TEAD1JAK3BTKTEAD3 | |
| SCHEMBL19229728 | 0.88 | JAK3 (0.38) | TEAD1JAK3BTK | |
| SCHEMBL19229727 | 0.88 | JAK3 (0.38) | TEAD1JAK3BTK | |
| SCHEMBL19229729 | 0.88 | JAK3 (0.38) | TEAD1JAK3BTK | |
| SCHEMBL17426256 | 0.85 | BTK (0.40) | TEAD1JAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018002-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018002-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2024-06-25 | — | — | US | disclosed |
| US-11976075-B2 | Inhibitors of the MYST family of lysine acetyl transferases | Isosterix, Inc. | 2024-05-07 | — | — | US | disclosed |
| US-11976075-B2 | Inhibitors of the MYST family of lysine acetyl transferases | Isosterix, Inc. | 2024-05-07 | — | — | US | disclosed |
| US-20230303580-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. | 2023-09-28 | — | — | US | disclosed |
| US-20230303580-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. | 2023-09-28 | — | — | US | disclosed |
| WO-2023172737-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC | 2023-02-09 | — | — | US | disclosed |
| WO-2022117051-A1 | MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 北京鞍石生物科技有限责任公司 | 2022-06-09 | — | — | WO | disclosed |
| US-20180072688-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180072688-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2018-03-15 | — | — | US | disclosed |
| US-9879003-B2 | Host targeted inhibitors of dengue virus and other viruses | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-07-27 | — | — | US | disclosed |
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-9145387-B2 | ERK inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150166532-A1 | HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-18 | — | — | US | disclosed |
| US-20130005745-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC (US) | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | TEAD1 3933/4885JAK3 110/4885BTK 172/4885 |
| US-12018002-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | TEAD1 3933/4885JAK3 110/4885BTK 172/4885 |
| US-20150166532-A1 | HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES | RPL17, RPL26, RPL35 | TEAD1 1198/4885JAK3 1373/4885BTK 1606/4885 |
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, RASGRP1 | TEAD1 223/4885JAK3 333/4885BTK 537/4885 |
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, BCL9 | TEAD1 3282/4885JAK3 182/4885BTK 1/4885 |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | TEAD1 4/4885JAK3 2919/4885BTK 1796/4885 |
| US-20230303580-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | KAT6A, KAT6B, KAT2A | TEAD1 114/4885JAK3 3688/4885BTK 3707/4885 |
| US-20180072688-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | TEAD1 3933/4885JAK3 110/4885BTK 172/4885 |
| US-20130005745-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | TEAD1 3166/4885JAK3 72/4885BTK 1/4885 |
| US-20170210729-A1 | ERK INHIBITORS AND USES THEREOF | MAP3K20, MAP3K1, MAPK3 | TEAD1 1389/4885JAK3 178/4885BTK 121/4885 |
| US-11976075-B2 | Inhibitors of the MYST family of lysine acetyl transferases | KAT6A, KAT6B, KAT2A | TEAD1 114/4885JAK3 3688/4885BTK 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.